2018
Botulinum Toxin in Restless Legs Syndrome—A Randomized Double-Blind Placebo-Controlled Crossover Study
Mittal SO, Machado D, Richardson D, Dubey D, Jabbari B. Botulinum Toxin in Restless Legs Syndrome—A Randomized Double-Blind Placebo-Controlled Crossover Study. Toxins 2018, 10: 401. PMID: 30274305, PMCID: PMC6215171, DOI: 10.3390/toxins10100401.Peer-Reviewed Original ResearchConceptsRestless legs syndromePain scoresCrossover studyLegs syndromePlacebo-controlled crossover studyDouble-blind placeboPatient Global ImpressionVisual analog scalePrevious smaller studiesCommon movement disorderQuality of lifeIncobotulinumtoxin APlacebo groupRLS symptomsAnalog scaleGlobal ImpressionOnabotulinumtoxin ALife QuestionnaireTibialis anteriorBotulinum toxinNormal salineMovement disordersRLS scoresSmall studyFemoris muscle
2017
The nature, consequences, and management of neurological disorders in chronic kidney disease
Jabbari B, Vaziri ND. The nature, consequences, and management of neurological disorders in chronic kidney disease. Hemodialysis International 2017, 22: 150-160. PMID: 28799704, DOI: 10.1111/hdi.12587.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseNeurological disordersNeurological symptomsKidney diseaseImpaired blood-brain barrierDiffuse white matter diseasePeripheral neurological symptomsRestless legs syndromeCentral neurological symptomsBlood-brain barrierWhite matter diseaseCentral nervous systemReflex myoclonusNeurological complicationsPeripheral neuropathyBrain edemaCortical myoclonusHemodynamic disordersLegs syndromePeripheral originBasal gangliaBrain barrierSubcortical lesionsMovement disordersSubcortical pathology
2015
Incobotulinum toxin-A (inco-A) in restless legs syndrome (RLS) - a randomized double blind cross over study (P7.295)
Rostami R, Machado D, Richardson D, Jabbari B. Incobotulinum toxin-A (inco-A) in restless legs syndrome (RLS) - a randomized double blind cross over study (P7.295). Neurology 2015, 84 DOI: 10.1212/wnl.84.14_supplement.p7.295.Peer-Reviewed Original Research